. 2020 Mar 27;182(6):583–594. doi: 10.1530/EJE-19-0762
This work is licensed under a Table 5.
Baseline characteristics of early and late responders.Response defined as the first occurrence of a reduction of mean GH to <1.0 µg/L and normalization of IGF-I after initiation of pasireotide in the core or extension phase. Data are presented as n (%) unless indicated otherwise.
| First response | Long-acting pasireotide 40 mg, n = 57 | Long-acting pasireotide 60 mg, n = 54 | Crossover to pasireotide, n = 62 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| ≤3 months | >3–6 months | >6 months | ≤3 months | >3–6 months | >6 months | ≤3 months | >3–6 months | >6 months | |
| n | 3 | 2 | 15 | 7 | 4 | 15 | 3 | 3 | 12 |
| Age, years* | 50.3 (4.9) | 50.5 (2.1) | 45.9 (14.74) | 55.0 (17.0) | 39.3 (11.3) | 45.9 (9.15) | 53.3 (8.39) | 43.7 (18.0) | 42.2 (14.3) |
| Baseline GH, µg/L* | 9.2 (7.0) | 5.2 (3.4) | 5.0 (2.9) | 6.8 (3.6) | 5.1 (2.7) | 4.1 (2.0) | 4.6 (1.0) | 4.8 (2.3) | 4.9 (1.7) |
| Baseline IGF-I* | 390.1 (45.8) | 442.2 (228.0) | 592.8 (133.6) | 658.8 (233.5) | 477.8 (108.1) | 626.7 (155.4) | 645.3 (72.8) | 633.7 (174.0) | 592.4 (161.4) |
| Sex, n (%) | |||||||||
| Male | 2 (66.7) | 1 (50.0) | 7 (46.7) | 3 (42.9) | 2 (50.0) | 6 (40.0) | 3 (100.0) | 2 (66.7) | 6 (50.0) |
| Female | 1 (33.3) | 1 (50.0) | 8 (53.3) | 4 (57.1) | 2 (50.0) | 9 (60.0) | 0 (0.0) | 1 (33.3) | 6 (50.0) |
| Tumour volume category at baseline, n (%) | |||||||||
| Microadenoma† | 2 (66.7) | 2 (100.0) | 11 (73.3) | 4 (57.1) | 4 (100.0) | 7 (46.7) | 1 (33.3) | 1 (33.3) | 11 (91.7) |
| Macroadenoma‡ | 0 (0.0) | 0 (0.0) | 1 (6.7) | 0 (0.0) | 0 (0.0) | 1 (6.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Missing | 1 (33.3) | 0 (0.0) | 3 (20.0) | 3 (42.9) | 0 (0.0) | 7 (46.7) | 2 (66.7) | 2 (66.7) | 1 (8.3) |
*Data are presented as mean (S.D.); †corresponding to a tumour diameter of ≤10 mm; ‡corresponding to a tumour diameter of >10 mm.